| Literature DB >> 29321021 |
Mario Alberto Pérez-Díaz1,2, Phaedra Silva-Bermudez3, Binisa Jiménez-López1, Valentín Martínez-López3, Yaaziel Melgarejo-Ramírez1, Ana Brena-Molina1, Clemente Ibarra3, Isabel Baeza2, M Esther Martínez-Pardo4, M Lourdes Reyes-Frías4, Erik Márquez-Gutiérrez1, Cristina Velasquillo1, Gabriel Martínez-Castañon5, Fidel Martinez-Gutierrez6, Roberto Sánchez-Sánchez7.
Abstract
BACKGROUND: Treatment of severe or chronic skin wounds is an important challenge facing medicine and a significant health care burden. Proper wound healing is often affected by bacterial infection; where biofilm formation is one of the main risks and particularly problematic because it confers protection to microorganisms against antibiotics. One avenue to prevent bacterial colonization of wounds is the use of silver nanoparticles (AgNPs); which have proved to be effective against non-multidrug-resistant and multidrug-resistant bacteria. In addition, the use of mesenchymal stem cells (MSC) is an excellent option to improve wound healing due to their capability for differentiation and release of relevant growth factors. Finally, radiosterilized pig skin (RPS) is a biomatrix successfully used as wound dressing to avoid massive water loss, which represents an excellent carrier to deliver MSC into wound beds. Together, AgNPs, RPS and MSC represent a potential dressing to control massive water loss, prevent bacterial infection and enhance skin regeneration; three essential processes for appropriate wound healing with minimum scaring.Entities:
Keywords: Anti-biofilm nanocomposites for wound healing; Mesenchymal stem cells; Radioesterilized pig skin; Silver nanoparticles
Mesh:
Substances:
Year: 2018 PMID: 29321021 PMCID: PMC5761131 DOI: 10.1186/s12951-017-0331-0
Source DB: PubMed Journal: J Nanobiotechnology ISSN: 1477-3155 Impact factor: 10.435
Fig. 1Physical characterization of silver nanoparticles (AgNPs). a Zeta potential, b hydrodynamic diameter (dynamic light scattering), c general shape (transmission electron micrograph) and d surface plasmon resonance (SPR) values for synthesized AgNPs
Minimum inhibitory concentrations
| Bacteria | Antibiotic or AgNPs | MIC ± SD (µg/mL) |
|---|---|---|
| AgNPs | 4.66 ± 1.15 | |
| Ceftazidime | 74.66 ± 18.47 | |
| AgNPs | 4.00 ± 0.0 | |
| Ceftazidime | 0.25 ± 0.0 | |
| AgNPs | 6.00 ± 2.00 | |
| Oxacillin | 128.00 ± 0.0 | |
| AgNPs | 7.30 ± 1.15 | |
| Oxacillin | 9.30 ± 2.30 |
Table shows minimum inhibitory concentrations of silver nanoparticles in solution and of antibiotics against clinical bacteria strains, HCR-392861 and INR-16-1700, and against reference bacteria strains ATCC 25922 and ATCC 29212
AgNPs silver nanoparticles, MIC minimum inhibitory concentration, SD standard deviation, G Gram-positive bacteria and G Gram-negative bacteria
Elemental composition of RPS and RPS-AgNPs nanocomposites as measured from electron-dispersive X-ray spectroscopy (EDS)
| Sample | C (at.%) | O (at.%) | N (at.%) | Ag (at.%) | S (at.%) |
|---|---|---|---|---|---|
| RPS | 54.44 ± 0.39 | 25.15 ± 0.18 | 19.98 ± 0.32 | 0.0 | 0.37 ± 0.02 |
| RPS-AgNPs-125 | 65.09 ± 2.44 | 26.25 ± 2.40 | 8.03 ± 6.03 | 0.59 ± 0.28 | 0.32 ± 0.24 |
| RPS-AgNPs-250 | 64.64 ± 1.07 | 29.84 ± 1.68 | 0.00 | 0.91 ± 0.19 | 0.00 |
| RPS-AgNPs-500 | 72.17 ± 3.46 | 26.74 ± 3.46 | 0.00 | 1.16 ± 1.083 | 0.00 |
| RPS-AgNPs-1000 | 64.90 ± 2.65 | 29.55 ± 2.65 | 0.00 | 5.65 ± 3.84 | 0.00 |
Data are presented as mean ± standard deviation after Au subtraction from EDS spectra
at.% atomic percentage, C carbon, O oxygen, N nitrogen, Ag silver, S sulfur
Fig. 2Characterization of RPS and RPS-AgNPs nanocomposites by scanning electron microscopy (SEM). Figure shows representative SEM micrographs (backscattered electrons) of RPS and RPS-AgNPs nanocomposites samples with different AgNPs concentration
Fig. 3Nanocomposites silver release characterization. Figure shows silver release over time from AgNPs-RPS nanocomposites incubated in deionized water as determined by a UV–Vis spectroscopy (420 nm) and b atomic absorption spectrometry
Fig. 4Inhibition halos of RPS-AgNPs nanocomposites by Kirby–Bauer assay. For both bacterial strains tested a Staphylococcus aureus (INR-16-1700) and b Stenotrophomonas maltophilia (HCR-392861), inhibition halos were dependent on AgNPs concentration of nanocomposites. Inhibition halos increased with increasing AgNPs concentration. c All nanocomposites (RPS-AgNPs-125, RPS-AgNPs-250, RPS-AgNPs-500 and RPS-AgNPs-1000) showed significantly higher inhibition halos than RPS; *p < 0.05 ANOVA, Tukey pos hoc test
Inhibition halos of RPS and RPS-AgNPs nanocomposites
| Sample | Bacteria | |
|---|---|---|
| Inhibition halos (mm) ± SD | ||
| RPS | 0 | 0 |
| RPS-AgNPs-125 | 8 ± 0 | 8 ± 1.73 |
| RPS-AgNPs-250 | 8.33 ± 1.53 | 9 ± 0.58 |
| RPS-AgNPs-500 | 9.67 ± 0.58 | 10 ± 0 |
| RPS-AgNPs-1000 | 11.33 ± 0.58 | 11 ± 1 |
RPS radiosterilized pig skin, RPS-AgNPS radiosterilized pig skin-Ag nanoparticles, SD standard deviation
Fig. 5Anti-biofilm activity of RPS-AgNPs nanocomposites. a Left-side set of photographs shows nanocomposites inhibition of biofilm formation against Staphylococus aureus (INR-16-1700), while; right-side set of photographs shows the inhibition effect of nanocomposites against Stenotrophomona maltophila (HCR-392861). Numbers on each photograph represent inoculum (biofilm disaggregation from nanocomposites) serial dilutions in saline solution, from 3 representing 1 × 10−3 v/v dilution to 10 representing 1 × 10−10 v/v dilution. b Graph shows quantitative analysis of biofilm inhibition against S. aureus (INR-16-1700) and S. maltophilia (INR-16-1700), presenting the Log 10 of the number of colony forming units (CFU) counted from dilution 8 vs nanocomposite from where biofilm was disaggregated); *p < 0.05 ANOVA, Tukey pos hoc test
Fig. 6Immunophenotype of human adipose-derived mesenchymal stem cells by flow citometry. Data shown correspond to percentage of human adipose-derived mesenchymal stem cells (ADMSC) labeled with primary monoclonal antibodies conjugated to a fluorochrome. Upper panel graphs show that ADMSC were positive for the expression of mesenchymal stem cells markers, CD90-FITC, CD73-APC, CD105-PE; 94.65% of cells were positive for co-expression of CD73-APC/CD90-FITC. Lower panel graphs show that ADMSC were negative for expression of hematopoietic stem cell markers, CD45FITC, CD34PE and CD14PerCP; only less than 1% of cells were positive for CD45FITC/CD34PE co-expression
Fig. 7Viability of adipose-derived mesenchymal stem cells cultured on nanocomposites. a representative micrographs of cell viability assays at 24 h of culture; live cells (calcein positive cells) are marked in green and dead cells (EthD-1 positive cells) are marked in red. CTL (control) corresponds to cells cultured on culture multiwell plates. Graph b shows cell viability percentage for each experimental condition. Graph c shows the total number of cells (live and dead) present on CTL, RPS and RPS-AgNPs nanocomposites after 24 h of culture. Graph d shows the number of viable cells detached from CTL, RPS and RPS-AgNPs nanocomposites at different culture times (cell proliferation curves), for up to 5 days of culture. Graph e shows the amount of metabolically active cells (as indirectly evaluated from absorbance measurements by MTT assay) over time, after cells exposure to RPS or AgNPs-RPS supernatants or CTL (cells exposed to fresh DMEM complemented with 10% FBS and 1% penicillin/streptomycin): For all graphs, ***p < 0.0001vs CTL; ANOVA, Tukey post hoc test